Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

Spremljeno u:
Bibliografski detalji
Izdano u:Transl Oncol
Glavni autori: Baidoun, Firas, Merjaneh, Zahi, Abd-Elhay, Fatma Abd-Elshahed, Kamel, Mohamed Gomaa
Format: Artigo
Jezik:Inglês
Izdano: Neoplasia Press 2021
Teme:
Commentary
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8214216/
https://ncbi.nlm.nih.gov/pubmed/34147028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2021.101156
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items